Evidence map›Paper›PMID 36205622›Full record

ArticleCell cycle (Georgetown, Tex.)2023

CST/Polα/primase-mediated fill-in synthesis at DSBs.

Zachary Mirman, Sarah Cai, Titia de Lange

Open access · hybridAbstract read
In one paragraph

Article in Cell cycle (Georgetown, Tex.), 2023. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 7 papers.

0numbers the graph read from it
0cells of the map it votes in
7citing papers in PubMed
1.4field-weighted citation impact, top 19% of its field
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

7 citing papers in PubMed, 16 citations in OpenAlex.

  1. Article
  2. eLife · 2024
    Article
  3. Article
  4. Article
  5. Article
  6. Review
  7. Review
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

3 authors at 2 institutions in 1 country.

Zachary MirmanLaboratory for Cell Biology and Genetics, The Rockefeller University, New York, NY, USA.
Sarah CaiLaboratory for Cell Biology and Genetics, The Rockefeller University, New York, NY, USA.
Titia de LangeLaboratory for Cell Biology and Genetics, The Rockefeller University, New York, NY, USA.ORCID 0000-0002-9267-367X
Rockefeller University · USBrigham and Women's Hospital · US

Funding

Genome instability in cancer: telomeres and DNA repairR35CA210036 · NCI · ROCKEFELLER UNIVERSITY · PI Titia de Lange · 2016 to 2026
$10.8M
Genome Integrity Through the Cell Cycle in Homeostasis and CancerK00CA245720 · NCI · BRIGHAM AND WOMEN'S HOSPITAL · PI MIRMAN, ZACHARY KENNETH · 2022 to 2025
$397k
NCI NIH HHS K00 CA245720NCI NIH HHS R35 CA210036
6 · The paper itself

Abstract

DNA double-strand breaks (DSBs) pose a major threat to the genome, so the efficient repair of such breaks is essential. DSB processing and repair is affected by 53BP1, which has been proposed to determine repair pathway choice and/or promote repair fidelity. 53BP1 and its downstream effectors, RIF1 and shieldin, control 3' overhang length, and the mechanism has been a topic of intensive research. Here, we highlight recent evidence that 3' overhang control by 53BP1 occurs through fill-in synthesis of resected DSBs by CST/Polα/primase. We focus on the crucial role of fill-in synthesis in BRCA1-deficient cells treated with PARPi and discuss the notion of fill-in synthesis in other specialized settings and in the repair of random DSBs. We argue that - in addition to other determinants - repair pathway choice may be influenced by the DNA sequence at the break which can impact CST binding and therefore the deployment of Polα/primase fill-in.

Indexed as

DNA Breaks, Double-StrandedDNA PrimaseDNA End-Joining RepairDNA RepairTumor Suppressor p53-Binding Protein 1DNA PrimaseTumor Suppressor p53-Binding Protein 153BP1CSTDSB repairPolα/primase

Identifiers

PMID36205622
PMCPMC9879193
OpenAlexW4303432248

What OpenQuestion holds

Textmetadata
LicenceCC BY-NC-ND
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.